For: | Carvalho-Filho RJ, Feldner ACC, Silva AEB, Ferraz MLG. Management of hepatitis C in patients with chronic kidney disease. World J Gastroenterol 2015; 21(2): 408-422 [PMID: 25593456 DOI: 10.3748/wjg.v21.i2.408] |
---|---|
URL: | https://www.wjgnet.com/1007-9327/full/v21/i2/408.htm |
Number | Citing Articles |
1 |
Wahiba Guenifi, Abdelkader Gasmi, Abdelmadjid Lacheheb. Epidemiological and Clinical Factors Associated with Spontaneous Clearance of Hepatitis C Virus. Middle East Journal of Digestive Diseases 2021; 13(4): 321 doi: 10.34172/mejdd.2021.241
|
2 |
A. Oruc, A. Ersoy. Transplantation Opportunities of Hepatitis C Virus–Seropositive Patients on the Kidney Waiting List. Transplantation Proceedings 2018; 50(10): 3181 doi: 10.1016/j.transproceed.2018.04.044
|
3 |
Pavlina Dzekova-Vidimliski, Aleksandar Sikole. Hepatitis C Virus Infection in Maintenance Hemodialysis Patients: Recommendations for Diagnostics and Treatment. The International Journal of Artificial Organs 2016; 39(12): 590 doi: 10.5301/ijao.5000548
|
4 |
Arogundade F. Abiola. Chronic Kidney Disease in Disadvantaged Populations. 2017; : 191 doi: 10.1016/B978-0-12-804311-0.00020-0
|
5 |
Taeang Arai, Masanori Atsukawa, Akihito Tsubota, Tadashi Ikegami, Noritomo Shimada, Keizo Kato, Hiroshi Abe, Tomomi Okubo, Norio Itokawa, Chisa Kondo, Shigeru Mikami, Toru Asano, Yoshimichi Chuganji, Yasushi Matsuzaki, Hidenori Toyoda, Takashi Kumada, Etsuko Iio, Yasuhito Tanaka, Katsuhiko Iwakiri. Efficacy and safety of ombitasvir/paritaprevir/ritonavir combination therapy for genotype 1b chronic hepatitis C patients complicated with chronic kidney disease. Hepatology Research 2018; 48(7): 549 doi: 10.1111/hepr.13058
|
6 |
Jakeline Ribeiro Barbosa, Vanessa Faria Cortes, Moyra Machado Portilho, Juliana Custódio Miguel, Vanessa Alves Marques, Cristianne Sousa Bezerra, Natalia Vasconcelos de Souza, Danielle Malta Lima, Jeová Keny Baima Colares, Lia Laura Lewis-Ximenez, Elisabeth Lampe, Livia Melo Villar. Performance of point of care assays for hepatitis B and C viruses in chronic kidney disease patients. Journal of Clinical Pathology 2018; 71(10): 879 doi: 10.1136/jclinpath-2018-205024
|
7 |
E. Morales, J.M. Cánovas, T. Cavero, P. Auñón, E. Gutiérrez. Afectación renal en las vasculitis, el lupus eritematoso y las enfermedades sistémicas. Medicine - Programa de Formación Médica Continuada Acreditado 2015; 11(82): 4902 doi: 10.1016/j.med.2015.06.012
|
8 |
Chisa Kondo, Masanori Atsukawa, Akihito Tsubota, Noritomo Shimada, Hiroshi Abe, Toru Asano, Kai Yoshizawa, Tomomi Okubo, Yoshimichi Chuganji, Yoshio Aizawa, Etsuko Iio, Yasuhito Tanaka, Katsuhiko Iwakiri. Daclatasvir and asunaprevir for genotype 1b chronic hepatitis C patients with chronic kidney disease. Hepatology Research 2017; 47(11): 1165 doi: 10.1111/hepr.12879
|
9 |
Adriana Dejman, Marco A. Ladino, David Roth. Treatment and management options for the hepatitis C virus infected kidney transplant candidate. Hemodialysis International 2018; 22(S1) doi: 10.1111/hdi.12646
|
10 |
Qinghua Ji, Xudong Chu, Yugui Zhou, Xuan Liu, Wei Zhao, Wei Ye. Safety and efficacy of grazoprevir/elbasvir in the treatment of acute hepatitis C in hemodialysis patients. Journal of Medical Virology 2022; 94(2): 675 doi: 10.1002/jmv.27374
|
11 |
Elena Laura Iliescu, Adriana Mercan-Stanciu, Letitia Toma. Safety and efficacy of direct-acting antivirals for chronic hepatitis C in patients with chronic kidney disease. BMC Nephrology 2020; 21(1) doi: 10.1186/s12882-020-1687-1
|
12 |
Yi-Chun Chen, Chung-Yi Li, Shiang-Jiun Tsai, Yen-Chun Chen. Anti-hepatitis C virus therapy in chronic kidney disease patients improves long-term renal and patient survivals. World Journal of Clinical Cases 2019; 7(11): 1270-1281 doi: 10.12998/wjcc.v7.i11.1270
|
13 |
Jolanta Malyszko, Jacek Zawierucha, Wojciech Marcinkowski, Tomasz Prystacki, Teresa Dryl-Rydzynska, Jacek S. Malyszko, Joanna Matuszkiewicz-Rowinska. The prevalence of hepatitis C and B among patients on hemodialysis and on renal transplantation waiting list in Poland has significantly decreased during the last 10 years. International Urology and Nephrology 2018; 50(8): 1555 doi: 10.1007/s11255-018-1897-7
|
14 |
Pavlina Dzekova-Vidimliski, Igor G. Nikolov, Nadica Matevska-Geshkovska, Sami Mena, Lionel Rostaing, Aleksandar Dimovski, Aleksandar Sikole. Single nucleotide polymorphisms near IL28B gene and response to treatment of chronic hepatitis C in hemodialysis patients. Renal Failure 2015; 37(7): 1180 doi: 10.3109/0886022X.2015.1061872
|
15 |
Arun Rajasekaran, Ricardo A. Franco, Edgar T. Overton, Brendan M. McGuire, Graham C. Towns, Jayme E. Locke, Deirdre L. Sawinski, Emmy K. Bell. Updated Pathway to Micro-elimination of Hepatitis C Virus in the Hemodialysis Population. Kidney International Reports 2021; 6(7): 1788 doi: 10.1016/j.ekir.2021.04.015
|
16 |
Chris Bellamy, Alastair D. Burt. Macsween's Pathology of the Liver. 2018; : 966 doi: 10.1016/B978-0-7020-6697-9.00015-7
|
17 |
Ladan Golestaneh, Joel Neugarten. Dual Organ Duel: The Hepatorenal Axis. Advances in Chronic Kidney Disease 2017; 24(4): 253 doi: 10.1053/j.ackd.2017.05.009
|
18 |
Byung Seok Lee, Myeong Jun Song, Jung Hyun Kwon, Tae Hee Lee, Ji Woong Jang, Seok Hyun Kim, Sae Hwan Lee, Hong Soo Kim, Ji Hoon Kim, Seok Bae Kim, Soon Young Ko, Do Seon Song. Efficacy and Safety of Daclatasvir and Asunaprevir in Patients with Hepatitis C Virus Genotype 1b Infection on Hemodialysis. Gut and Liver 2019; 13(2): 191 doi: 10.5009/gnl18240
|
19 |
Hélio Ranes de Menezes Filho, Ana Luiza de Souza Bierrenbach, Maria Ligia Damato Capuani, Alfredo Mendrone, Adele Schwartz Benzaken, Soraia Mafra Machado, Marielena Vogel Saivish, Ester Cerdeira Sabino, Steven Sol Witkin, Maria Cássia Mendes-Corrêa, Yury E. Khudyakov. Impact on mortality of being seropositive for hepatitis C virus antibodies among blood donors in Brazil: A twenty-year study. PLOS ONE 2019; 14(12): e0226566 doi: 10.1371/journal.pone.0226566
|
20 |
Sean M. McConachie, Sheila M. Wilhelm, Pramodini B. Kale-Pradhan. New direct-acting antivirals in hepatitis C therapy: a review of sofosbuvir, ledipasvir, daclatasvir, simeprevir, paritaprevir, ombitasvir and dasabuvir. Expert Review of Clinical Pharmacology 2016; 9(2): 287 doi: 10.1586/17512433.2016.1129272
|
21 |
Christopher O.C. Bellamy, Alastair D. Burt. MacSween's Pathology of the Liver. 2024; : 1039 doi: 10.1016/B978-0-7020-8228-3.00015-6
|
22 |
Natasha Silva Constancio, Maria Lucia Gomes Ferraz, Carmen Tzanno Branco Martins, Angiolina Campos Kraychete, Paulo Lisboa Bitencourt, Marcelo Mazza do Nascimento. Hepatitis C in Hemodialysis Units: diagnosis and therapeutic approach. Brazilian Journal of Nephrology 2019; 41(4): 539 doi: 10.1590/2175-8239-jbn-2018-0177
|
23 |
Hee Yeon Seo, Myeong-Sook Seo, Sun-Young Yoon, Jong Wook Choi, Soon Young Ko. Full-dose sofosbuvir plus low-dose ribavirin for hepatitis C virus genotype 2-infected patients on hemodialysis. The Korean Journal of Internal Medicine 2020; 35(3): 559 doi: 10.3904/kjim.2018.338
|
24 |
Anita Kohli, Ali Alshati, Fawaz Georgie, Richard Manch, Robert G. Gish. Direct-acting antivirals for the treatment of chronic hepatitis C in patients with chronic kidney disease. Therapeutic Advances in Gastroenterology 2016; 9(6): 887 doi: 10.1177/1756283X16665254
|
25 |
Min Li, Peiyuan Wang, Chunhua Yang, Wenguo Jiang, Xiaodan Wei, Xinbo Mu, Xuri Li, Jia Mi, Geng Tian. A systematic review and meta-analysis: Does hepatitis C virus infection predispose to the development of chronic kidney disease?. Oncotarget 2017; 8(6): 10692 doi: 10.18632/oncotarget.12896
|
26 |
Adele Schwartz Benzaken, Renato Girade, Elisa Catapan, Gerson Fernando Mendes Pereira, Elton Carlos de Almeida, Simone Vivaldini, Neide Fernandes, Homie Razavi, Jonathan Schmelzer, Maria Lucia Ferraz, Paulo Roberto Abrão Ferreira, Mario Guimarães Pessoa, Ana Martinelli, Francisco José Dutra Souto, Nick Walsh, Maria Cassia Mendes-Correa. Hepatitis C disease burden and strategies for elimination by 2030 in Brazil. A mathematical modeling approach. The Brazilian Journal of Infectious Diseases 2019; 23(3): 182 doi: 10.1016/j.bjid.2019.04.010
|
27 |
Joel Neugarten, Ladan Golestaneh. Chronic Renal Disease. 2020; : 863 doi: 10.1016/B978-0-12-815876-0.00053-X
|
28 |
Hideki Fujii, Hiroyuki Kimura, Masayuki Kurosaki, Chitomi Hasebe, Takehiro Akahane, Hitoshi Yagisawa, Keizo Kato, Hideo Yoshida, Jun Itakura, Shinya Sakita, Takashi Satou, Kazuhiko Okada, Atsunori Kusakabe, Yuji Kojima, Masahiko Kondo, Atsuhiro Morita, Akihiro Nasu, Takashi Tamada, Hiroaki Okushin, Haruhiko Kobashi, Keiji Tsuji, Kouji Joko, Chikara Ogawa, Yasushi Uchida, Akeri Mitsuda, Tetsuro Sohda, Yasushi Ide, Namiki Izumi. Efficacy of daclatasvir plus asunaprevir in patients with hepatitis C virus infection undergoing and not undergoing hemodialysis. Hepatology Research 2018; 48(9): 746 doi: 10.1111/hepr.13070
|
29 |
Soon Young Ko, Won Hyeok Choe. Management of hepatitis C viral infection in chronic kidney disease patients on hemodialysis in the era of direct-acting antivirals. Clinical and Molecular Hepatology 2018; 24(4): 351 doi: 10.3350/cmh.2017.0063
|